These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

560 related articles for article (PubMed ID: 31195062)

  • 1. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis.
    Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ
    J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients.
    Agarwal K; Castells L; Müllhaupt B; Rosenberg WMC; McNabb B; Arterburn S; Camus G; McNally J; Stamm LM; Brainard DM; Mani Subramanian G; Mariño Z; Dufour JF; Forns X
    J Hepatol; 2018 Sep; 69(3):603-607. PubMed ID: 29886154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
    Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
    J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
    Asselah T; Shafran SD; Bourgeois S; Lai CL; Mathurin P; Willems B; Nguyen MH; Davis MN; Huang KC; Svarovskaia E; Osinusi A; McNally J; Brainard DM; Shaikh OS; Tran TT
    J Viral Hepat; 2019 Oct; 26(10):1229-1232. PubMed ID: 31216086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.
    Hezode C; Reau N; Svarovskaia ES; Doehle BP; Shanmugam R; Dvory-Sobol H; Hedskog C; McNally J; Osinusi A; Brainard DM; Miller MD; Mo H; Roberts SK; O'Leary JG; Shafran SD; Zeuzem S
    J Hepatol; 2018 May; 68(5):895-903. PubMed ID: 29221887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
    Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis.
    Bhat MA; Mir AN; Parry MA; Parray IA
    Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):570-575. PubMed ID: 38725207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
    Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
    Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
    Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
    J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
    Esteban R; Pineda JA; Calleja JL; Casado M; Rodríguez M; Turnes J; Morano Amado LE; Morillas RM; Forns X; Pascasio Acevedo JM; Andrade RJ; Rivero A; Carrión JA; Lens S; Riveiro-Barciela M; McNabb B; Zhang G; Camus G; Stamm LM; Brainard DM; Subramanian GM; Buti M
    Gastroenterology; 2018 Oct; 155(4):1120-1127.e4. PubMed ID: 29958855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
    Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
    J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
    Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK
    Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
    Foster GR; Afdhal N; Roberts SK; Bräu N; Gane EJ; Pianko S; Lawitz E; Thompson A; Shiffman ML; Cooper C; Towner WJ; Conway B; Ruane P; Bourlière M; Asselah T; Berg T; Zeuzem S; Rosenberg W; Agarwal K; Stedman CA; Mo H; Dvory-Sobol H; Han L; Wang J; McNally J; Osinusi A; Brainard DM; McHutchison JG; Mazzotta F; Tran TT; Gordon SC; Patel K; Reau N; Mangia A; Sulkowski M; ;
    N Engl J Med; 2015 Dec; 373(27):2608-17. PubMed ID: 26575258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
    Curry MP; O'Leary JG; Bzowej N; Muir AJ; Korenblat KM; Fenkel JM; Reddy KR; Lawitz E; Flamm SL; Schiano T; Teperman L; Fontana R; Schiff E; Fried M; Doehle B; An D; McNally J; Osinusi A; Brainard DM; McHutchison JG; Brown RS; Charlton M;
    N Engl J Med; 2015 Dec; 373(27):2618-28. PubMed ID: 26569658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.
    Jonas MM; Romero R; Rosenthal P; Lin CH; Verucchi G; Wen J; Balistreri WF; Whitworth S; Bansal S; Leung DH; Narkewicz MR; Gonzalez-Peralta RP; Mangia A; Karnsakul W; Rao GS; Shao J; de Jong J; Parhy B; Osinusi A; Kersey K; Murray KF; Sokal EM; Schwarz KB
    J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1342-1354. PubMed ID: 38644678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
    Lawitz E; Reau N; Hinestrosa F; Rabinovitz M; Schiff E; Sheikh A; Younes Z; Herring R; Reddy KR; Tran T; Bennett M; Nahass R; Yang JC; Lu S; Dvory-Sobol H; Stamm LM; Brainard DM; McHutchison JG; Pearlman B; Shiffman M; Hawkins T; Curry M; Jacobson I
    Gastroenterology; 2016 Nov; 151(5):893-901.e1. PubMed ID: 27486034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.
    Feld JJ; Jacobson IM; Hézode C; Asselah T; Ruane PJ; Gruener N; Abergel A; Mangia A; Lai CL; Chan HL; Mazzotta F; Moreno C; Yoshida E; Shafran SD; Towner WJ; Tran TT; McNally J; Osinusi A; Svarovskaia E; Zhu Y; Brainard DM; McHutchison JG; Agarwal K; Zeuzem S;
    N Engl J Med; 2015 Dec; 373(27):2599-607. PubMed ID: 26571066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.